Iterum Therapeutics, which is developing oral and IV antibiotics for drug-resistant bacterial infections, raised $80 million by offering 6.15 million shares at $13, below the range of $14 to $16.
It had planned to offer 5.3 million shares, so with the additional shares, its deal size remained unchanged at $80 million.
Iterum Therapeutics plans to list on the Nasdaq under the symbol ITRM. Leerink Partners and RBC Capital Markets acted as lead managers on the deal.
